BOSTON (

TheStreet

) -- Stocks gained Tuesday, buoyed by strong car sales at

Ford

(F) - Get Report

in February. Here are three stocks that hit 52-week highs.

3. Biogen Idec

(BIIB) - Get Report

rose 0.9% to $57.31, recording a high of $57.47. Shares of the biotechnology company have gained 4.3% during the past month.

The numbers

: Fourth-quarter profit increased 48% to $306 million, or $1.06 a share, as revenue grew 5.4% to $1.1 billion. Biogen Idec's operating margin extended from 33% to 40%. Its balance sheet contains $1.3 billion of cash and $1.1 billion of debt.

The stock

: Biogen Idec has appreciated 30% during the past year, trailing major U.S. indices. The stock trades at a price-to-projected-earnings ratio of 12, a discount to biotech peers. Its PEG ratio, a measure of value relative to growth, of 0.5 is on par with competitors. A PEG ratio below 1 implies cheap shares.

2. DirecTV

(DTV)

climbed 1.2% to $34.61, achieving a high of $34.79. Shares of the satellite-television company have advanced 9.5% during the past month.

The numbers

: DirecTV swung to a fourth-quarter loss of $32 million, or 3 cents a share, from a profit of $332 million, or 31 cents, a year earlier. Revenue increased 13% to $6 billion. DirecTV's operating margin expanded from 11% to 14%. The company holds $2.6 billion of cash and $8.6 billion of debt.

The stock

: DirecTV has increased 78% during the past year, beating major benchmarks. The stock sells for a price-to-projected-earnings ratio of 12, a discount to competitors. Its PEG ratio of 0.3 reflects a 75% discount to the industry average.

1. Teva Pharmaceutical Industries

(TEVA) - Get Report

rose 0.6% to $60.95, touching a high of $61.64. Shares of the drugmaker have rallied 5.9% during the past month.

The numbers

: Teva swung to a fourth-quarter profit of $379 million, or 42 cents a share, from a loss of $688 million, or 88 cents, a year earlier. Revenue increased 33% to $3.8 billion. Teva's operating margin declined from 25% to 24%. Its balance sheet houses $2.2 billion of cash and $5.6 billion of debt.

The stock

: Teva has surged 40% during the past year, trailing U.S. indices. The stock trades at a price-to-projected-earnings ratio of 12, on par with peers. Its PEG ratio of 0.3 indicates a 65% discount to the industry average.

-- Reported by Jake Lynch in Boston.